[Impact of prophylactic HPV vaccines on dermatology and venereology].
Prophylactic HPV L1 VLP quadrivalent and bivalent vaccines are of great importance for patients seen by dermatologists and venereologists. Both vaccines protect against HPV16- and HPV18-associated anogenital cancers, as well as cancers of the mouth, the upper respiratory tract and skin, especially of the fingers and periungual region. The quadrivalent HPV6, 11, 16, 18 vaccine also prevents anogenital warts (condylomata acuminata) which are the most common benign tumors of this body region. HPV-vaccination (Gardasil) has been approved in Germany since October 2006 for young girls between 9-16 and young women between 16-26 years of age. Many experts feel that boys and young men should also be vaccinated. Men would profit from a vaccine that protects against HPV infections, especially anogenital warts, as well as penile and anal carcinomas. In immunosuppressed organ transplant recipients and HIV-positive individuals, HPV can be widespread, chronic and often rapidly progressive to malignant tumors; thus these groups would greatly benefit from HPV immunization.
Gross
G
G
Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum AöR, Universität Rostock, Augustenstrasse 80-84, 18055 Rostock, Deutschland. gerd.gross@med.uni-rostock.de
D003880:Dermatology / Q000639:trends*; D005858:Germany; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends; D015229:Sexually Transmitted Diseases, Viral / Q000517:prevention & control*; D017193:Skin Diseases, Viral / Q000517:prevention & control*; D014686:Venereology / Q000639:trends*
D053918:Papillomavirus Vaccines